Meta-analysis of case-control studies for NQO1 Pro187Ser polymorphisms and lung, bladder, and colorectal cancer risk
| . | No. studies . | OR* for variant genotype (95% CI) . | Test for heterogeneity P . | Egger's test P . | ||||
|---|---|---|---|---|---|---|---|---|
| Lung cancer | ||||||||
| Overall | ||||||||
| CT | 14† | 1.04 (0.92-1.19)‡ | 0.02 | 0.59 | ||||
| TT | 14† | 1.07 (0.98-1.16)‡ | 0.03 | 0.69 | ||||
| CT/TT | 19§ | 0.97 (0.86-1.10)‡ | <0.01 | 0.79 | ||||
| White | ||||||||
| CT | 8∥ | 1.07 (0.98-1.16) | 0.87 | 0.07 | ||||
| TT | 8∥ | 1.19 (0.94-1.50) | 0.44 | 0.60 | ||||
| CT/TT | 11¶ | 1.04 (0.96-1.13) | 0.34 | 0.81 | ||||
| Asian | ||||||||
| CT | 7** | 1.00 (0.70-1.43)‡ | 0.01 | 0.10 | ||||
| TT | 7** | 0.95 (0.58-1.55)‡ | <0.01 | 0.81 | ||||
| CT/TT | 8†† | 0.99 (0.72-1.34)‡ | <0.01 | 0.15 | ||||
| Black | ||||||||
| CT/TT | 3‡‡ | 0.95 (0.66-1.36) | 0.63 | 0.57 | ||||
| Bladder cancer | ||||||||
| Overall | ||||||||
| CT | 8§§ | 1.06 (0.90-1.25) | 0.10 | 0.19 | ||||
| TT | 8§§ | 1.27 (0.90-1.80) | 0.26 | 0.31 | ||||
| CT/TT | 8§§ | 1.09 (0.93-1.28) | 0.32 | 0.38 | ||||
| White | ||||||||
| CT | 6∥∥ | 1.19 (0.99-1.44) | 0.58 | 0.04¶¶ | ||||
| TT | 6∥∥ | 1.24 (0.81-1.90) | 0.11 | 0.18 | ||||
| CT/TT | 6∥∥ | 1.20 (1.00-1.43) | 0.69 | 0.29 | ||||
| Colorectal cancer | ||||||||
| Overall | ||||||||
| CT | 6*** | 1.15 (1.01-1.32) | 0.33 | 0.82 | ||||
| TT | 6*** | 0.93 (0.68-1.26) | 0.12 | 0.72 | ||||
| CT/TT | 6*** | 1.13 (0.99-1.28) | 0.20 | 0.84 | ||||
| White | ||||||||
| CT | 5††† | 1.18 (1.03-1.37) | 0.34 | 0.88 | ||||
| TT | 5††† | 1.10 (0.77-1.57) | 0.24 | 0.89 | ||||
| CT/TT | 5††† | 1.18 (1.02-1.35) | 0.36 | 0.77 | ||||
| . | No. studies . | OR* for variant genotype (95% CI) . | Test for heterogeneity P . | Egger's test P . | ||||
|---|---|---|---|---|---|---|---|---|
| Lung cancer | ||||||||
| Overall | ||||||||
| CT | 14† | 1.04 (0.92-1.19)‡ | 0.02 | 0.59 | ||||
| TT | 14† | 1.07 (0.98-1.16)‡ | 0.03 | 0.69 | ||||
| CT/TT | 19§ | 0.97 (0.86-1.10)‡ | <0.01 | 0.79 | ||||
| White | ||||||||
| CT | 8∥ | 1.07 (0.98-1.16) | 0.87 | 0.07 | ||||
| TT | 8∥ | 1.19 (0.94-1.50) | 0.44 | 0.60 | ||||
| CT/TT | 11¶ | 1.04 (0.96-1.13) | 0.34 | 0.81 | ||||
| Asian | ||||||||
| CT | 7** | 1.00 (0.70-1.43)‡ | 0.01 | 0.10 | ||||
| TT | 7** | 0.95 (0.58-1.55)‡ | <0.01 | 0.81 | ||||
| CT/TT | 8†† | 0.99 (0.72-1.34)‡ | <0.01 | 0.15 | ||||
| Black | ||||||||
| CT/TT | 3‡‡ | 0.95 (0.66-1.36) | 0.63 | 0.57 | ||||
| Bladder cancer | ||||||||
| Overall | ||||||||
| CT | 8§§ | 1.06 (0.90-1.25) | 0.10 | 0.19 | ||||
| TT | 8§§ | 1.27 (0.90-1.80) | 0.26 | 0.31 | ||||
| CT/TT | 8§§ | 1.09 (0.93-1.28) | 0.32 | 0.38 | ||||
| White | ||||||||
| CT | 6∥∥ | 1.19 (0.99-1.44) | 0.58 | 0.04¶¶ | ||||
| TT | 6∥∥ | 1.24 (0.81-1.90) | 0.11 | 0.18 | ||||
| CT/TT | 6∥∥ | 1.20 (1.00-1.43) | 0.69 | 0.29 | ||||
| Colorectal cancer | ||||||||
| Overall | ||||||||
| CT | 6*** | 1.15 (1.01-1.32) | 0.33 | 0.82 | ||||
| TT | 6*** | 0.93 (0.68-1.26) | 0.12 | 0.72 | ||||
| CT/TT | 6*** | 1.13 (0.99-1.28) | 0.20 | 0.84 | ||||
| White | ||||||||
| CT | 5††† | 1.18 (1.03-1.37) | 0.34 | 0.88 | ||||
| TT | 5††† | 1.10 (0.77-1.57) | 0.24 | 0.89 | ||||
| CT/TT | 5††† | 1.18 (1.02-1.35) | 0.36 | 0.77 | ||||
The reference group are subjects with the genotype C/C.
Included: refs. 16, 26, 27, 29-34, 34, 38, 40, 41, 43, 44.
Estimates derived from random effects models.
Included: refs. 16, 26-34, 36, 38-45.
Included: refs. 16, 26, 27, 29, 32, 38, 40, 44.
Included: refs. 16, 26-29, 32, 38-40, 44, 45.
Included: refs. 29-31, 33, 34, 41, 43.
Included: refs. 29-31, 33, 34, 36, 41, 43.
Included: refs. 28, 38, 42.
Included: refs. 46-50, 52-54.
Included: refs. 46, 48, 50, 52-54.
Publication bias was not suggested by Begg's funnel plot.
Included: refs. 30, 55-59.
Included: refs. 55-59.